{
    "nct_id": "NCT06124118",
    "official_title": "A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC",
    "inclusion_criteria": "Step 1: Pre-Chemoradiation Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).\n* Clinical AJCC (AJCC, 8th ed.) stage IIIA or IIIB, or IIIC NSCLC with unresectable disease. Staging FDG-PET/CT and MRI brain (preferred) or CT head with contrast scan must have been completed within 60 days prior to initiation of concurrent CRT. Unresectable disease must be determined by a multi-disciplinary team unless, in the opinion of the treating investigator, the subject's disease is clearly unresectable. Subjects who refuse surgery will be considered to have unresectable disease.\n* Able to operate the NovoTTF-200T System independently or with the help of a caregiver.\n* Eligible to receive standard of care chemoradiation per institutional standards.\n* Subject must have measurable disease by RECIST 1.1 criteria by CT.\n* ECOG Performance Status ≤ 1.\n* Adequate organ function as defined as:\n* Hematologic:\n\n  * Absolute neutrophil count (ANC) ≥ 1500/mm3\n  * Platelet count ≥ 100,000/mm3\n  * Hemoglobin ≥ 10 g/dL (transfusions are allowed for Device Duration Level 2 only if anemia is due to prior therapy.)\n* Hepatic:\n\n  * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN) or direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN.\n  * AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN\n  * Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.\n* Renal:\n\n  * Estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula:\n* Males:\n\n  * ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)\n* Females:\n\n  * (((140-age)×weight[kg])/(serum creatinine [mg/dL]×72))×0.85\n* For subjects of childbearing potential:\n\n  * Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n* Subjects < 50 years of age:\n\n  * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n  * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n  * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n* Subjects ≥ 50 years of age:\n\n  * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n  * Had radiation-induced menopause with last menses >1 year ago; or\n  * Had chemotherapy-induced menopause with last menses >1 year ago; or\n  * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 4.6.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nStep 2: Pre-Consolidative Immunotherapy Phase Inclusion Criteria\n\n* The subject must have previously completed and been eligible for Step 1 registration.\n* Completion of post-chemoradiation CT scan and RECIST 1.1 assessment.\n* Eligible to receive consolidation immunotherapy per institutional standards and Investigator judgement.\n* Able to operate the NovoTTF-200T System independently or with the help of a caregiver.\n* ECOG Performance Status ≤ 1.\n* Adequate organ function as defined as:\n* Hematologic:\n\n  * Absolute neutrophil count (ANC) ≥ 1500/mm3\n  * Platelet count ≥ 100,000/mm3\n  * Hemoglobin ≥ 10 g/dL (transfusions are allowed for Device Duration Level 2 only if anemia is due to prior therapy with concurrent chemoradiation.)\n* Hepatic:\n\n  * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN) or direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN.\n  * AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN\n  * Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.\n* Renal:\n\n  * Estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula:\n* Males:\n\n  * ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)\n* Females:\n\n  * (((140-age)×weight[kg])/(serum creatinine [mg/dL]×72))×0.85\n* Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior cancer therapy (except for alopecia or fatigue) unless considered clinically not significant and/or stable by the treating investigator.\n* Resolution of any pneumonitis from prior radiation therapy to < grade 1 per the treating investigator.\nHealthy volunteers allowed\nMust have minimum age of 22 Years",
    "exclusion_criteria": "Step 1: Pre-Chemoradiation Phase Exclusion Criteria\n\n* Prior thoracic radiation, including breatbreast radiation.\n* Prior exposure to TTFields.\n* Prior systemic immunotherapy or radiotherapy for NSCLC.\n* nown underlying skin hypersensitivity or known allergy to skin adhesives or hydrogel.\n* Known hypersensitivity to radiation due to genetic susceptibility, connective tissue disease, or any other cause.\n* Receiving other investigational agents.\n* Major surgery (per treating investigator) within 4 weeks prior to starting study drug or who have not fully recovered from major surgery. Note: Biopsies without significant complications will not be considered major surgery.\n* The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6).\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n* Cardiovascular disorders:\n\n  * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious or clinically significant cardiac arrhythmias.\n  * Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n  * QTc prolongation defined as a QTcF > 500 ms.\n  * Known congenital long QT.\n  * Left ventricular ejection fraction < 50%.\n  * Uncontrolled hypertension defined as persistent blood pressure of ≥ 160/90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n  * Implanted pacemaker, defibrillator or other electrical medical devices;\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, [subjects may not receive the drug through a feeding tube], social/ psychological issues, etc.)\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n* Active known infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C. Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* History of allogenic stem cell or solid organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, uveitis, etc.]). The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia\n  * Patients with endocrine disorders with controlled disease on hormone replacement therapy (e.g. adrenal, thyroid, or pituitary replacement therapy)\n  * Any chronic skin condition that does not require systemic therapy\n  * Patients without active disease in the last 5 years may be included but only after consultation with the principal investigator.\n  * Patients with celiac disease controlled by diet alone\n* Current or prior use of immunosuppressive medication within 14 days of cycle one day one, EXCEPT for the following permitted steroids:\n\n  * Intranasal, inhaled, topical steroids, eye drops, or local steroid injection (e.g., intra-articular injection);\n  * Systemic corticosteroids at physiologic doses ≤ 10mg/day of prednisone or equivalent;\n  * Steroids as premedication for hypersensitivity reactions (e.g., computed tomography (CT) scan premedication).\n* Subjects taking prohibited medications as described in Section 5.11. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.\n* History of exudative pleural effusions, regardless of cytology.\n* Peripheral neuropathy > grade 1 for patients receiving concurrent carboplatin and paclitaxel with radiation.\n\nStep 2 Pre-Consolidative Immunotherapy Phase Exclusion Criteria\n\n* Subjects who in the investigators opinion had disease progression following concurrent chemoradiation.\n* Known underlying skin hypersensitivity or known allergy to skin adhesives or hydrogel.\n* Major surgery (per treating investigator) 4 weeks prior to starting study drug or who have not fully recovered from major surgery.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n* Cardiovascular disorders:\n\n  * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious or clinically significant cardiac arrhythmias.\n  * Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n  * QTc prolongation defined as a QTcF > 500 ms.\n  * Known congenital long QT.\n  * Left ventricular ejection fraction < 50%.\n  * Uncontrolled hypertension defined as persistent blood pressure of ≥ 160/90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n  * Implanted pacemaker, defibrillator or other electrical medical devices;\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, [subjects may not receive the drug through a feeding tube], social/ psychological issues, etc.)\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* History of allogenic stem cell or solid organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, uveitis, etc.]).\n* The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia\n  * Patients with endocrine disorders with controlled disease on hormone replacement therapy (e.g. adrenal, thyroid, or pituitary replacement therapy)\n  * Any chronic skin condition that does not require systemic therapy\n  * Patients without active disease in the last 5 years may be included but only after consultation with the principal investigator\n  * Patients with celiac disease controlled by diet alone.\n* Current or prior use of immunosuppressive medication within 14 days of cycle one day one, EXCEPT for the following permitted steroids:\n\n  * Intranasal, inhaled, topical steroids, eye drops, or local steroid injection (e.g., intra-articular injection)\n  * Systemic corticosteroids at physiologic doses ≤ 10mg/day of prednisone or equivalent\n* History of exudative pleural effusions, regardless of cytology.",
    "miscellaneous_criteria": ""
}